MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 1, 2010, Pages 124-134

  Nicol, Mark Patrick ^a   Grobler, Liesl Anne ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; MVA 85A; TISSUE PLASMINOGEN ACTIVATOR; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTHRALGIA; BCG VACCINATION; CATTLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL TRIAL; COW; DIARRHEA; DRUG EFFICACY; DRUG SYNTHESIS; EX VIVO STUDY; FEVER; FLOW CYTOMETRY; GUINEA PIG; HEADACHE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOPATHOLOGY; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; POLYMERASE CHAIN REACTION; REVIEW; RHESUS MONKEY; TUBERCULOSIS; VIRUS STRAIN;

ACYLTRANSFERASES; ANTIGENS, BACTERIAL; BCG VACCINE; CLINICAL TRIALS AS TOPIC; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VIRAL VACCINES;

ANIMALIA;

EID: 76749126266     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Variation in protection by BCG: Implications of and for heterologous immunity. Fine EM Lancet 1995 346 8986 1339-1345
2. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine. Blanchard TJ, Alcami A, Andrea P, Smith GL J Gen Virol 1998 79 Pt 5 1159-1167
3. Chronic bacterial infections: Living with unwanted guests. Young D, Hussell T, Dougan G Nat Immunol 2002 3 11 1026-1032
4. TB vaccines for the world-Second international conference, Vienna, Austria. IDdb author IDDB MEETIN G RE PORT 2006 April 19-21
5. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of γ interferon. Radosevic K, Wieland CW, Rodriguez A, Weverling GJ, Mintardjo R, Gillissen G, Vogels R, Skeiky YAW, Hone DM, Sadoff JC, van der Poll TD et al Infect Immun 2007 75 8 4105-4115
6. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Beveridge NER, Price DA, Casazza JP, Pathan AA, Sander CR, Asher TE, Ambrozak DR, Precopio ML, Scheinberg P, Alder NC, Roederer M et al Eur J Immunol 2007 37 11 3089-3100
7. SSI, Intercell and Aeras announce start of clinical trial for novel vaccine candidate against TB. Statens Serum Institut Press Release 2007 December 04
8. Phacilitate Vaccine Forum Geneva 2008, Geneva, Switzerland. Petrovsky N IDDB MEETIN G RE PORT 2008 May 14-16
9. Emergent BioSolutions and the University of Oxford form joint venture to develop an advanced tuberculosis vaccine with funding from Wellcome Trust and Aeras Global TB Vaccine Foundation. Emergent BioSolutions Inc Press Release 2008 July 23
10. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, Lang T, Veldsman A, Hatherill M, Merwe L, Fletcher HA et al J Infect Dis 2008 198 4 544-552
11. Aeras and Crucell announce TB vaccine clinical trial in Kenya; promising vaccine candidate advances to phase II safety study in South Africa. Crucell NV Press Release 2008 October 17
12. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8+-and CD4+-T-cell epitopes from antigen 85A. McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AVS Infect Immun 2002 70 3 1623-1626
13. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and Bacille Calmette-Guerin. Vordermeier HM, Rhodes SG, Dean G, Goonetilleke N, Huygen K, Hill AVS, Hewinson RG, Gilbert SC Immunology 2004 112 3 461-470
14. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AVS Nat Med 2004 10 11 1240-1244
15. Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, Huygen K, Ottenhoff THM, Franken KLMC, Andersen P Tuberculosis 2005 85 1-2 29-38
16. Boosting BCG with MVA85A: The first candidate subunit vaccine for tuberculosis in clinical trials. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AVS Tuberculosis 2005 85 1-2 47-52
17. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Williams A, Goonetilleke NP, McShane H, Clark SO, Hatch G, Gilbert SC, Hill AVS Infect Immun 2005 73 6 3814-3816
18. Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: Different boosting intervals and implications for efficacy trials. Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Beveridge NER, Whelan KT, Hill AVS, McShane H PLoS Clin Trials 2007 2 10 e1052
19. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries DJ, Donkor SA, Fletcher HA, Hammond AS, Lienhardt C, Adegbola RA, McShane H et al PLoS ONE 2008 3 8 e2921
20. Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-ß1. Fletcher HA, Pathan AA, Berthoud TK, Dunachie SJ, Whelan KT, Alder NC, Sander CR, Hill AVS, McShane H Vaccine 2008 26 41 5269-5275
21. GlaxoSmithKline: Product development pipeline. GlaxoSmithKline plc Company World Wide Web site 2009 February 28
22. New TB vaccine candidate enters phase IIb proof-ofconcept trial in South Africa. Aeras Global TB Vaccine Foundation Press Release 2009 April 22
23. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Sander CR, Pathan AA, Beveridge NER, Poulton I, Minassian A, Alder N, van Wijgerden J, Hill AVS, Gleeson FV, Davies RJO, Pasvol G et al Am J Respir Crit Care Med 2009 179 8 724-733
24. Oxford-Emergent Tuberculosis Consortium signs commercial license agreement with Vivalis to explore production of MVA85A TB vaccine candidate using EB66 cell line. Emergent BioSolutions Inc Press Release 2009 May 05
25. Vivalis and Oxford-Emergent tuberculosis Consortium sign commercial license agreement. Oxford-Emergent Tuberculosis Consortium Ltd Press Release 2009 May 05
26. Oxford-Emergent Tuberculosis Consortium signs commercial license agreement with ProBioGen to explore production of MVA85A TB vaccine candidate using AGE1.CR.pIX cell line. Oxford-Emergent Tuberculosis Consortium Ltd Press Release 2009 May 05
27. Defined tuberculosis vaccine, mtb72f/as02a, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci USA 2009 106 7 2301-2306
28. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: Comparison with boosting with a new TB vaccine, MVA85A. Whelan KT, Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Hill AVS, McShane H PLoS ONE 2009 4 6 e5934
29. Mva.85a boosting of BCG and an attenuated, phop deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. Verreck FAW, Vervenne RAW, Kondova I, van Kralingen KW, Remarque EJ, Braskamp G, van der Werff NM, Kersbergen A, Ottenhoff THM, Heidt PJ, Gilbert SC et al PLoS ONE 2009 4 4 e5264
30. Immunogenicity and protective efficacy of prime-boost regimens with recombinant ?ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus Ankara expressing M-tuberculosis antigen 85a against murine tuberculosis. Tchilian EZ, Desel C, Forbes EK, Bandermann S, Sander CR, Hill AVS, McShane H, Kaufmann SHE Infect Immun 2009 77 2 622-631
31. Safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MVA85A, in healthy Gambian infants previously vaccinated with BCG. Ota MO, Owolabi OA, Odutola OA, Owiate PK, Adegbola RA, McShane H ANNU CONF VACCINE RES 2009 12 Abs P56
32. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G Lancet 2006 368 9547 1575-1580
33. Patients with active tuberculosis often have different strains in the same sputum specimen. Warren RM, Victor TC, Streicher EM, Richardson M, Beyers N, Gey van Pittius N, van Helden PD Am J Respir Crit Care Med 2004 169 5 610-614
34. Tuberculosis. Maartens G, Wilkinson RJ Lancet 2007 370 9604 2030-2043
35. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: A meta-analysis. Rodrigues LC, Diwan VK, Wheeler JG Int J Epidemiol 1993 22 6 1154-1158
36. Tuberculosis vaccine development: Goals, immunological design, and evaluation. Hoft DF Lancet 2008 372 9633 164-175
37. Host genetics of mycobacterial diseases in mice and men: Forward genetic studies of BCG-osis and tuberculosis. Fortin A, Abel L, Casanova JL, Gros P Annu Rev Genomics Hum Genet 2007 8 163-192
38. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of Bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AVS J ImmunOL 2003 171 3 1602-1609
39. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. Forbes EK, Sander C, Ronan EO, McShane H, Hill AVS, Beverley PCL, Tchilian EZ J ImmunOL 2008 181 7 4955-4964
40. What animal models teach humans about tuberculosis. Dharmadhikari AS, Nardell EA Am J Respir Cell Mol Biol 2008 39 5 503-508
41. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, Thacker T, Gilbert SC, McShane H, Hill AVS, Xing Z, Hewinson RG Infect Immun 2009 77 8 3364-3373
42. Modified vaccinia virus Ankara as antigen delivery system: How can we best use its potential? Drexler I, Staib C, Sutter G Curr Op in Biotechnol 2004 15 6 506-512
43. A comparison of IFNγ detection methods used in tuberculosis vaccine trials. Beveridge NER, Fletcher HA, Hughes J, Pathan AA, Scriba TJ, Minassian A, Sander CR, Whelan KT, Dockrell HM, Hill AVS, Hanekom WA et al Tuberculosis 2008 88 6 631-640
44. Modified vaccinia Ankara-expressing Ag85A, a novel TB vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, Keyser A, Moyo S, Brittain N, Lawrie A, Gelderbloem S et al Eur J Immunol 2009 40 1 279-290
45. Therapeutic vaccination with MVA-HIV-1 nef elicits Nefspecific T-helper cell responses in chronically HIV-1 infected individuals. Cosma A, Nagaraj R, Buhler S, Hinkula J, Busch DH, Sutter G, Goebel FD, Erfle V Vaccine 2003 22 1 21-29
46. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Mittrucker HW, Steinhoff U, Kohler A, Krause M, Lazar D, Mex P, Miekley D, Kaufmann SHE PRO C NATL ACAD SCI USA 2007 104 30 12434-12439
47. Multifunctional Th1 cells define a correlate of vaccinemediated protection against Leishmania major. Darrah PA, Patel DT, De Luca PM, Lindsay RWB, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M et al Nat Med 2007 13 7 843-850
48. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Skeiky YA, Dietrich J, Lasco TM, Stagliano K, Goetz MA, Cantarero L, Basaraba RJ, Bang P, Kromann I, McMclain JB, Sadoff JC et al Vaccine 2010 28 4 1084-1093
49. Genetic dissection of immunity to mycobacteria: The human model. Casanova JL, Abel L Annu Rev Immunol 2002 20 581-620
50. Global tuberculosis control: Epidemiology, strategy, financing: Key points. World Health Organization WHO: WORL D HEALT H RE P 2009 1-4
51. Part I: Item I: Business: Intellectual property and licenses. Emergent BioSolutions Inc FORM 10-K 2009 March 06 26
52. Epidemiology of HIV-associated tuberculosis. Lawn SD, Churchyard G CURR OPIN HIV AI DS 2009 4 4 325-333
53. Tuberculosis: Pathophysiology, clinical features, and diagnosis. Knechel NA CRIT CARE NURSE 2009 29 2 34-43
54. Human Mycobacterium bovis infection in the United Kingdom: Incidence, risks, control measures and review of the zoonotic aspects of bovine tuberculosis. de la Rua-Domenech R TU BER CULOSIS 2006 86 2 77-109
55. Robert Koch and the white death: From tuberculosis to tuberculin. Gradmann C MI CRO BES INFE CT 2006 8 1 294-301
56. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. Hanekom WA, Dockrell HM, Ottenhoff TH, Doherty TM, Fletcher H, McShane H, Weichold FF, Hoft DF, Parida SK, Fruth UJ PLOS MED (ONLINE ) 2008 5 7 e145
57. Personal communication: Robert J Wilkinson-Principal investigator of the South African, phase IIb, multicenter clinical trial of MVA-85A in HIV-infected adults. University of Cape Town COMPANY COMMUNICATION 2010 January 06